# BridgeBio Pharma, Inc.: financial statements, quarterly

BBIO · Nasdaq · CIK 1743881 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/bbio.md) · [Financials](/companies/bbio/financials.md) · [Filings](/companies/bbio/filings.md) · [Insiders](/companies/bbio/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/bbio/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.7 d](/filings/0001743881-26-000009.md) | [211](/filings/0000950170-25-060314.md) | [2.2](/filings/0000950170-25-103192.md) | [2.7](/filings/0001743881-25-000012.md) | [5.9 d](/filings/0001743881-26-000009.md) | [117](/filings/0001743881-26-000019.md) | [111](/filings/0001743881-26-000027.md) | [121](/filings/0001743881-26-000034.md) | [154 d](/filings/0001743881-26-000009.md) | [195](/filings/0001743881-26-000019.md) | [244](/filings/0001743881-26-000027.md) | [353](/filings/0001743881-26-000034.md) |
| Cost of revenue | $m | [0.6 d](/filings/0001743881-26-000009.md) | [0.6](/filings/0000950170-25-060314.md) | [0.6](/filings/0000950170-25-103192.md) | [0.6](/filings/0001743881-25-000012.md) | [2.1 d](/filings/0001743881-26-000009.md) | [2.6](/filings/0001743881-26-000019.md) | [3.7](/filings/0001743881-26-000027.md) | [6.6](/filings/0001743881-26-000034.md) | [8.1 d](/filings/0001743881-26-000009.md) | [9.9](/filings/0001743881-26-000019.md) | [15.0](/filings/0001743881-26-000027.md) | [20.5](/filings/0001743881-26-000034.md) |
| Research and development | $m | [130 d](/filings/0001743881-26-000009.md) | [141](/filings/0000950170-25-060314.md) | [115](/filings/0000950170-25-103192.md) | [120](/filings/0001743881-25-000012.md) | [130 d](/filings/0001743881-26-000009.md) | [111](/filings/0001743881-26-000019.md) | [111](/filings/0001743881-26-000027.md) | [113](/filings/0001743881-26-000034.md) | [116 d](/filings/0001743881-26-000009.md) | [127](/filings/0001743881-26-000019.md) | [149](/filings/0001743881-26-000027.md) | [144](/filings/0001743881-26-000034.md) |
| Selling, general and administrative | $m | [47.6 d](/filings/0001743881-26-000009.md) | [65.8](/filings/0000950170-25-060314.md) | [59.5](/filings/0000950170-25-103192.md) | [68.8](/filings/0001743881-25-000012.md) | [94.8 d](/filings/0001743881-26-000009.md) | [106](/filings/0001743881-26-000019.md) | [129](/filings/0001743881-26-000027.md) | [138](/filings/0001743881-26-000034.md) | [158 d](/filings/0001743881-26-000009.md) | [164](/filings/0001743881-26-000019.md) | [186](/filings/0001743881-26-000027.md) | [201](/filings/0001743881-26-000034.md) |
| Operating income | $m | [(177) d](/filings/0001743881-26-000009.md) | [0.3](/filings/0000950170-25-060314.md) | [(176)](/filings/0000950170-25-103192.md) | [(192)](/filings/0001743881-25-000012.md) | [(226) d](/filings/0001743881-26-000009.md) | [(104)](/filings/0001743881-26-000019.md) | [(134)](/filings/0001743881-26-000027.md) | [(145)](/filings/0001743881-26-000034.md) | [(140) d](/filings/0001743881-26-000009.md) | [(106)](/filings/0001743881-26-000019.md) | [(107)](/filings/0001743881-26-000027.md) | [(11.6)](/filings/0001743881-26-000034.md) |
| Interest expense | $m | [20.3 d](/filings/0000950170-24-018811.md) | [23.5](/filings/0000950170-24-052165.md) | [22.9](/filings/0000950170-24-089326.md) | [23.1](/filings/0001743881-25-000012.md) | [21.5 d](/filings/0001743881-26-000009.md) | [18.1](/filings/0001743881-26-000019.md) | [11.6](/filings/0001743881-26-000027.md) | [11.7](/filings/0001743881-26-000034.md) | [11.6 d](/filings/0001743881-26-000009.md) | [12.9](/filings/0001743881-26-000019.md) | [13.3](/filings/0001743881-26-000027.md) | [13.3](/filings/0001743881-26-000034.md) |
| Income tax | $m | [0.0 d](/filings/0001743881-26-000009.md) | [0.0](/filings/0000950170-25-060314.md) | [0.0](/filings/0000950170-25-103192.md) | [0.0](/filings/0001743881-25-000012.md) | [1.2 d](/filings/0001743881-26-000009.md) | [0.0](/filings/0000950170-25-060314.md) | [2.1](/filings/0001743881-26-000027.md) | [(1.5)](/filings/0001743881-26-000034.md) | [(0.1) d](/filings/0001743881-26-000009.md) | not reported | [0.0](/filings/0001743881-26-000027.md) | [1.2](/filings/0001743881-26-000034.md) |
| Net income | $m | [(170) d](/filings/0001743881-26-000009.md) | [(36.2)](/filings/0000950170-25-060314.md) | [(75.5)](/filings/0000950170-25-103192.md) | [(164)](/filings/0001743881-25-000012.md) | [(267) d](/filings/0001743881-26-000009.md) | [(170)](/filings/0001743881-26-000019.md) | [(184)](/filings/0001743881-26-000027.md) | [(183)](/filings/0001743881-26-000034.md) | [(201) d](/filings/0001743881-26-000009.md) | [(167)](/filings/0001743881-26-000019.md) | [(156)](/filings/0001743881-26-000027.md) | [(56.7)](/filings/0001743881-26-000034.md) |
| Diluted EPS | $ per share | not reported | [(0.20)](/filings/0000950170-25-060314.md) | [(0.39)](/filings/0000950170-25-103192.md) | [(0.86)](/filings/0001743881-25-000012.md) | not reported | [(0.88)](/filings/0001743881-26-000019.md) | [(0.95)](/filings/0001743881-26-000027.md) | [(0.95)](/filings/0001743881-26-000034.md) | not reported | [(0.84)](/filings/0001743881-26-000019.md) | [(0.78)](/filings/0001743881-26-000027.md) | [(0.42)](/filings/0001743881-26-000034.md) |
| Basic EPS | $ per share | not reported | [(0.20)](/filings/0000950170-25-060314.md) | [(0.39)](/filings/0000950170-25-103192.md) | [(0.86)](/filings/0001743881-25-000012.md) | not reported | [(0.88)](/filings/0001743881-26-000019.md) | [(0.95)](/filings/0001743881-26-000027.md) | [(0.95)](/filings/0001743881-26-000034.md) | not reported | [(0.84)](/filings/0001743881-26-000019.md) | [(0.78)](/filings/0001743881-26-000027.md) | [(0.42)](/filings/0001743881-26-000034.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:ProfitLoss, us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [376](/filings/0001743881-26-000009.md) | [475](/filings/0000950170-25-060314.md) | [408](/filings/0000950170-25-103192.md) | [266](/filings/0001743881-25-000012.md) | [681](/filings/0001743881-26-000009.md) | [541](/filings/0001743881-26-000019.md) | [749](/filings/0001743881-26-000027.md) | [643](/filings/0001743881-26-000034.md) | [570](/filings/0001743881-26-000034.md) | [880](/filings/0001743881-26-000019.md) | [678](/filings/0001743881-26-000027.md) | [1,533](/filings/0001743881-26-000034.md) |
| Current assets | $m | [478](/filings/0000950170-25-024119.md) | [783](/filings/0000950170-24-052165.md) | [616](/filings/0000950170-24-089326.md) | [445](/filings/0000950170-24-124577.md) | [721](/filings/0001743881-26-000009.md) | [695](/filings/0000950170-25-060314.md) | [912](/filings/0000950170-25-103192.md) | [839](/filings/0001743881-25-000012.md) | [798](/filings/0001743881-26-000034.md) | [1,241](/filings/0001743881-26-000019.md) | [1,093](/filings/0001743881-26-000027.md) | [2,045](/filings/0001743881-26-000034.md) |
| Total assets | $m | [546](/filings/0000950170-25-024119.md) | [849](/filings/0000950170-24-052165.md) | [794](/filings/0000950170-24-089326.md) | [665](/filings/0000950170-24-124577.md) | [919](/filings/0001743881-26-000009.md) | [882](/filings/0000950170-25-060314.md) | [1,080](/filings/0000950170-25-103192.md) | [998](/filings/0001743881-25-000012.md) | [936](/filings/0001743881-26-000034.md) | [1,371](/filings/0001743881-26-000019.md) | [1,217](/filings/0001743881-26-000027.md) | [2,162](/filings/0001743881-26-000034.md) |
| Current liabilities | $m | [144](/filings/0000950170-25-024119.md) | [141](/filings/0000950170-24-052165.md) | [134](/filings/0000950170-24-089326.md) | [139](/filings/0000950170-24-124577.md) | [154](/filings/0001743881-26-000009.md) | [152](/filings/0000950170-25-060314.md) | [176](/filings/0000950170-25-103192.md) | [217](/filings/0001743881-25-000012.md) | [288](/filings/0001743881-26-000034.md) | [816](/filings/0001743881-26-000019.md) | [891](/filings/0001743881-26-000027.md) | [977](/filings/0001743881-26-000034.md) |
| Total liabilities | $m | [1,889](/filings/0000950170-25-024119.md) | [1,886](/filings/0000950170-24-052165.md) | [1,876](/filings/0000950170-24-089326.md) | [1,883](/filings/0000950170-24-124577.md) | [2,377](/filings/0001743881-26-000009.md) | [2,520](/filings/0000950170-25-060314.md) | [2,859](/filings/0000950170-25-103192.md) | [2,921](/filings/0001743881-25-000012.md) | [3,013](/filings/0001743881-26-000034.md) | [3,640](/filings/0001743881-26-000019.md) | [3,723](/filings/0001743881-26-000027.md) | [3,815](/filings/0001743881-26-000034.md) |
| Long-term debt | $m | [446](/filings/0000950170-25-024119.md) | [435](/filings/0000950170-24-052165.md) | [435](/filings/0000950170-24-089326.md) | [436](/filings/0000950170-24-124577.md) | [437](/filings/0000950170-25-103192.md) | [0.0](/filings/0000950170-25-060314.md) | [0.0](/filings/0000950170-25-103192.md) | [2,007](/filings/0001743881-25-000012.md) | [2,007](/filings/0001743881-26-000009.md) | [2,653](/filings/0001743881-26-000019.md) | [2,653](/filings/0001743881-26-000027.md) | [2,630](/filings/0001743881-26-000034.md) |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [(1,354)](/filings/0000950170-25-024119.md) | [(1,050)](/filings/0000950170-24-052165.md) | [(1,093)](/filings/0000950170-24-089326.md) | [(1,230)](/filings/0000950170-24-124577.md) | [(1,468)](/filings/0001743881-26-000009.md) | [(1,648)](/filings/0000950170-25-060314.md) | [(1,788)](/filings/0000950170-25-103192.md) | [(1,933)](/filings/0001743881-25-000012.md) | [(2,087)](/filings/0001743881-26-000034.md) | [(2,278)](/filings/0001743881-26-000019.md) | [(2,515)](/filings/0001743881-26-000027.md) | [(1,662)](/filings/0001743881-26-000034.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent, us-gaap:LongTermDebt
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(125) d](/filings/0001743881-26-000009.md) | [(220)](/filings/0000950170-25-060314.md) | [74.7 d](/filings/0000950170-25-103192.md) | [(181) d](/filings/0001743881-25-000012.md) | [(195) d](/filings/0001743881-26-000009.md) | [(199)](/filings/0001743881-26-000019.md) | [(80.7) d](/filings/0001743881-26-000027.md) | [(110) d](/filings/0001743881-26-000034.md) | [(56.4) d](/filings/0001743881-26-000009.md) | [(197)](/filings/0001743881-26-000019.md) | [(71.1) d](/filings/0001743881-26-000027.md) | [(44.2) d](/filings/0001743881-26-000034.md) |
| Capital expenditure | $m | [0.4 d](/filings/0001743881-26-000009.md) | [0.7](/filings/0000950170-25-060314.md) | [0.1 d](/filings/0000950170-25-103192.md) | [0.1 d](/filings/0001743881-25-000012.md) | [0.0 d](/filings/0001743881-26-000009.md) | [0.0](/filings/0001743881-26-000019.md) | [0.6 d](/filings/0001743881-26-000027.md) | [0.5 d](/filings/0001743881-26-000034.md) | [0.0 d](/filings/0001743881-26-000009.md) | [0.1](/filings/0001743881-26-000019.md) | [0.4 d](/filings/0001743881-26-000027.md) | [0.3 d](/filings/0001743881-26-000034.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | [0.0](/filings/0000950170-25-060314.md) | [0.0 d](/filings/0000950170-25-103192.md) | [0.0 d](/filings/0001743881-25-000012.md) | [0.0 d](/filings/0001743881-26-000009.md) | [48.3](/filings/0001743881-26-000019.md) | [0.0 d](/filings/0001743881-26-000027.md) | [0.0 d](/filings/0001743881-26-000034.md) | [0.0 d](/filings/0001743881-26-000009.md) | [82.5](/filings/0001743881-26-000019.md) | [128 d](/filings/0001743881-26-000027.md) | [42.5 d](/filings/0001743881-26-000034.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [153](/filings/0000950170-24-052165.md) | [161](/filings/0000950170-24-089326.md) | [163](/filings/0000950170-24-124577.md) | [179](/filings/0000950170-25-060314.md) | [188](/filings/0000950170-25-103192.md) | [189](/filings/0001743881-25-000012.md) | [190](/filings/0001743881-26-000019.md) | [191](/filings/0001743881-26-000027.md) | [192](/filings/0001743881-26-000034.md) | [195](/filings/0001743881-26-000019.md) | [196](/filings/0001743881-26-000027.md) | [196](/filings/0001743881-26-000034.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 194,800,782 at 2026-10-22, from the cover of the [10-Q filed 2026-10-29](/filings/0001743881-26-000034.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 19:20 ET. No prices; not investment advice.